CADTH Canadian Drug Expert Committee recommendation (final). Letermovir (Prevymis -- Merck Canada Inc.) indication : cytomegalovirus infection, prophylaxis.

The CADTH Canadian Drug Expert Committee (CDEC) recommends that letermovir be reimbursed for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).

Saved in:

Bibliographic Details
Online Access:	Full text
Corporate Author:	CADTH Canadian Drug Expert Committee (Author)
Format:	Electronic eBook
Language:	English
Published:	Ottawa (ON) : CADTH, 2018
Edition:	Version 1.0.
Series:	Common drug review clinical review report.
Subjects:	Cytomegalovirus Infections > drug therapy. Antiviral Agents > therapeutic use. Acetates > therapeutic use. Quinazolines > therapeutic use. Antibiotic Prophylaxis > methods. Hematopoietic Stem Cell Transplantation. Drug Costs.

CADTH Canadian Drug Expert Committee recommendation (final). Sebelipase alfa (Kanuma -- Alexion Pharmaceuticals, Inc.) indication : lysosomal acid lipase deficiency.

Version 1.0.

Published 2018

Full text

Electronic eBook

CADTH Canadian Drug Expert Committee recommendation (final). Letermovir (Prevymis -- Merck Canada Inc.) indication : cytomegalovirus infection, prophylaxis.

CADTH Canadian Drug Expert Committee recommendation (final). Sebelipase alfa (Kanuma -- Alexion Pharmaceuticals, Inc.) indication : lysosomal acid lipase deficiency.

Similar Items